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Background: High toxicity, morbidity and secondary malignancy render chemotherapy of neuroblastoma inefficient,
prompting the search for novel compounds. Nanovesicles offer great promise in imaging and treatment of cancer.
SapC-DOPS, a stable nanovesicle formed from the lysosomal protein saposin C and dioleoylphosphatidylserine possess
strong affinity for abundantly exposed surface phosphatidylserine on cancer cells. Here, we show that SapC-DOPS
effectively targets and suppresses neuroblastoma growth and elucidate the molecular mechanism of SapC-DOPS action
in neuroblastoma in vitro.
Methods: In vivo targeting of neuroblastoma was assessed in xenograft mice injected intravenously with fluorescently-
labeled SapC-DOPS. Xenografted tumors were also used to demonstrate its therapeutic efficacy. Apoptosis induction
in vivo was evaluated in tumor sections using the TUNEL assay. The mechanisms underlying the induction of apoptosis
by SapC-DOPS were addressed through measurements of cell viability, mitochondrial membrane potential (ΔΨM), flow
cytometric DNA fragmentation assays and by immunoblot analysis of second mitochondria-derived activator of
caspases (Smac), Bax, Cytochrome c (Cyto c) and Caspase-3 in the cytosol or in mitochondrial fractions of cultured
neuroblastoma cells.
Results: SapC-DOPS showed specific targeting and prevented the growth of human neuroblastoma xenografts in
mice. In neuroblastoma cells in vitro, apoptosis occurred via a series of steps that included: (1) loss of ΔΨM and
increased mitochondrial superoxide formation; (2) cytosolic release of Smac, Cyto c, AIF; and (3) mitochondrial
translocation and polymerization of Bax. ShRNA-mediated Smac knockdown and V5 peptide-mediated Bax inhibition
decreased cytosolic Smac and Cyto c release along with caspase activation and abrogated apoptosis, indicating that
Smac and Bax are critical mediators of SapC-DOPS action. Similarly, pretreatment with the mitochondria-stabilizing
agent bongkrekic acid decreased apoptosis indicating that loss of ΔΨM is critical for SapC-DOPS activity. Apoptosis
induction was not critically dependent on reactive oxygen species (ROS) production and Cyclophilin D, since pretreatment
with N-acetyl cysteine and cyclosporine A, respectively, did not prevent Smac or Cyto c release.
Conclusions: Taken together, our results indicate that SapC-DOPS acts through a mitochondria-mediated pathway
accompanied by an early release of Smac and Bax. Specific tumor-targeting capacity and anticancer efficacy of
SapC-DOPS supports its potential as a dual imaging and therapeutic agent in neuroblastoma therapy.
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Nanotechnology is transforming cancer therapy by im-
proving drug delivery, imaging and selective targeting of
tumor cells [1-3]. In the past, several attempts have been
made to formulate nanovesicles from components nor-
mally present in cells [4]. In this direction, SapC-DOPS, a
nanovesicle made from saposin C and dioleylphosphatidyl-
serine, is a unique protein-lipid complex that selectively
targets and kills human cancer cells in vitro and in vivo
[1,5-12]. Saposin C is an 80 kDa heat-stable, protease-
resistant protein containing distinct functional domains;
that functions as a co-activator of sphingolipid-degrading
lysosomal hydrolases (sphingomyelinase and acid β-
glucosidase) [13]. Owing to the presence of a fusogenic
domain comprising two amphipathic α − helices contain-
ing four Lys residues (K13, K17, K26, and K38), SapC ex-
hibits natural affinity towards negatively charged
phospholipids such as phosphatidylserine (PS). This inter-
action occurs at low pH (pKa of 5.3) and is critical for
SapC activation [13,14]. We have previously assembled
SapC and DOPS into stable nanovesicles and its efficacy
and safety profiles have been established in various forms
of cancer [1,5,6,8,12]. SapC-DOPS is hypothesized to bind
to exposed PS on the cancer cell surface and induce apop-
tosis by increasing intracellular ceramide level leading to
subsequent caspase activation [8]. However, the precise
intracellular pathway(s) mediating SapC-DOPS induced
apoptotic cancer cell death is still unknown.
Neuroblastoma accounts for 15% of all pediatric can-
cer mortalities and is the most common extracranial
tumor in young adults [15]. Aggressive chemotherapy
and radiation protocols have failed to improve the sur-
vival rates significantly in children with high-risk disease
[16]. Efficacy of chemotherapy in neuroblastoma is less
than satisfactory due to several factors such as high tox-
icity, severe morbidity and risk of secondary malignancy
[17]. Moreover, in patients with relapse the long-term
survival rates are < 50% emphasizing the need for novel,
non-genotoxic targeted therapies. Elevation of intracellular
ceramide, a known regulator of mitochondrial function,
was noticed during in vitro treatment of neuroblastoma
cell lines with SapC-DOPS [8]. Ceramide induces apop-
tosis via the mitochondrial pathway [18]. Mitochondria
play a central role in the induction of apoptosis by acting
as both a major amplification step and the principal site of
action for pro- and anti-apoptotic members of the Bcl-2
family [19]. Whereas the anti-apoptotic members (e.g.,Bcl-2
and Bcl-xL) confine apoptogenic proteins within the mito-
chondrial intermembrane space by promoting pore closure,
the pro-apoptotic proteins (e.g., Bax, Bak and Bid) that
translocate from the cytosol to mitochondria promote
pore opening [20]. In addition, it is known that these
pro-apoptotic molecules promote pore formation inde-
pendently or in combination with other mitochondrialproteins such as the voltage-dependent anion channel
(VDAC) effecting the release of apoptogenic proteins
such as Cyto c, Smac/Diablo and apoptosis inducing
factor (AIF) from the intermembrane space [21-23].
Final commitment to apoptosis is postulated to occur
by the following sequence of events: formation of pores
or channels in the outer mitochondrial membrane,
opening of pores, loss of mitochondrial membrane po-
tential (ΔΨM), apoptogenic protein release from mito-
chondria and caspase activation [24]. In this report we
evaluate the in vivo targeting and antitumor capacity of
SapC-DOPS in mice bearing neuroblastoma xeno-
grafts, and address the molecular mechanisms under-
lying neuroblastoma cell death after SapC-DOPS
exposure. Based on past observations, we test the hy-
pothesis that SapC-DOPS-induced apoptotic cell death
is caused by mitochondrial dysfunction, apoptogenic
protein release and caspase activation. Cell viability,
mitochondrial function and redistribution of apoptotic
proteins are assessed in vitro in the neuroblastoma cell
lines SK-N-SH and IMR-32, representative of non-
metastatic and metastatic neuroblastoma, respectively.
The in vivo efficacy of SapC-DOPS in suppressing
neuroblastoma growth and the insights obtained into its
mechanism of action support its potential as a novel
therapeutic agent for the treatment of neuroblastoma.Materials and methods
Reagents and antibodies
The following reagents and antibodies were used:
Bongkrekic acid (Santa Cruz Biotechnology, La Jolla,
CA), JC-1 (eBioscience, San Diego, CA), Cyclosporine A,
2′,7′-dichlorofluorescein acetate (DCFH-DA), N-acetyl
cysteine (Sigma, St.Louis, MO), Dioleylphosphatidylserine
(Avanti Lipids, Alabaster, AL), 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) ((Roche Diag-
nostics, Indianapolis, IN), and disuccinyl suberate
(Thermo Scientific Fischer, Rockford, IL). Anti-Bcl-2,
anti-β-Actin (Abcam, Cambridge, MA), anti-Cyto c
(eBioscience, San Diego, CA), anti-AIF, anti-caspase-3,
anti-cleaved caspase-3 (Cell Signaling Technology,
Boston, MA, anti-Survivin, Smac/Diablo, α-Tubulin
(Novus biological, Littleton, CO), anti-COX-4, anti-Bax
(N-20; Santa Cruz Biotechnology, La Jolla, CA), anti-
Bax (polymer-recognizing A67 clone; Sigma, St.Louis,
MO) and anti- cleaved PARP (Millipore, Bedford, MA).
Animal maintenance and experimental procedures
were carried out in accordance with the US National
Institute of health Guidelines for Use of Experimental
Animals and approved by the Institutional Animal
Care and Use Committee of the University of Cincin-
nati and Cincinnati Children's Hospital Medical
Center.
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nanovesicles
The procedures for production of SapC-DOPS nanovesi-
cles have been described in detail before [1,6-9]. Briefly,
recombinantly expressed and purified saposin C along
with solvent-dried dioleylphosphatidylserine were mixed
in acidic citrate-phosphate buffer and freshly assembled
into nanovesicles by bath sonication. The lipophilic, in-
frared dye CellVue Maroon (CVM) was added during
SapC-DOPS assembly to fluorescently label the nanove-
sicles for in vivo imaging of neuroblastoma human xeno-
grafts. The nanovesicles are stable for at least a week,
when stored at 4°C. TEM analysis for surface morph-
ology was performed as described earlier [25].
Mouse xenografts and cell culture
Human neuroblastoma CHLA-20 was a gift from
Thomas Inge (Cincinnati Children’s Hospital Medical
Center); the origin and culture conditions were previ-
ously described [26]. Athymic nude mice (nu/nu, NIH)
(15 mice per group), were injected with 7.5 × 106 cells
subcutaneously to initiate tumor growth. When tumors
reached a volume of 400 mm3, five doses of either SapC-
DOPS (SapC 4 mg/kg body weight, DOPS 2 mg/kg body
weight) or PBS (control) were intratumorally adminis-
tered once every 3 days. Tumor growth was assessed
periodically with a caliper, and after 16 days, tumors
were excised, weighted, and processed for hematoxylin
and eosin staining and apoptosis (TUNEL) assays.
The human neuroblastoma SK-N-SH and IMR-32 cell
lines were obtained from American Type Culture Collec-
tion and grown in AMEM supplemented with 10% FBS.
Human Schwann cells (ScienCell Research Laboratories,
Carlsbad, CA) were grown as recommended by the sup-
plier. After overnight attachment, cells were treated with
either DOPS or SapC-DOPS for concentration- or time-
dependence assays. Where indicated, cells were pretreated
for 60 min with bongkrekic acid, cyclosporine A or N-
acetyl cysteine.
Cell viability and apoptosis assays
Cell viability was assessed with a standard assay using the
tetrazolium dye MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide) as previously described [6]
three days after initiating treatment. The following
methods were employed to assess SapC-DOPS-induced
cell death: G6PD release assay (Life Technologies, Grand
Island, NY), was performed according to the manufac-
turer’s instructions, DAPI staining was performed as de-
scribed earlier [27], caspase activation through cleaved
caspase-3 and cleaved PARP fragments was evaluated by
Western blotting, and cell cycle analysis was performed on
a FACS Calibur (Becton Dickinson) in serum-starved, syn-
chronized cells after fixation with 80% ethanol at −20°C for20 min followed by staining with 100 μg/ml of RNase and
25 μg/ml of PI [28]. Cell cycle phase was analyzed with the
CellQuest-Pro software program (Becton Dickinson). In
vivo apoptosis was measured by TUNEL staining as
described earlier [8].
Evaluation of mitochondrial membrane potential (ΔΨM)
and ROS production
Following treatment with SapC-DOPS, cells in triplicate
were washed with PBS and evaluated for concentration-
and time-dependent changes in ΔΨM by resuspension
in fresh JC-1 containing medium, followed by 30 min in-
cubation in the dark at room temperature [28]. Fluores-
cence intensity was measured with excitation at 490 nm
and the emission monitored at 530 (monomer) and 590
(aggregate) nm, using a BMG microplate reader (BMG
Labtech, Inc., Durham, NC). The ratio between green
and red fluorescence provides an estimate of ΔΨM that
is independent of the mitochondrial mass. For the ROS
assay, cells treated with SapC-DOPS were exposed to
DCFH-DA for 15 min at 37°C. Fluorescence excitation
and emission wavelengths were set at 480 and 530 nm
respectively, using a BMG microplate reader (BMG
Labtech, Inc., Durham, NC). Mitochondrial superoxide
was detected using the fluorescent Mito-Sox probe (Invi-
trogen). Cells were incubated in Hank’s buffer with
2 μM MitoSox-Red for 30 min at 37°C in a 5% CO2 at-
mosphere, washed with PBS and the fluorescence
assessed by flow cytometry. Positive control cells were
pretreated with 20 μM Antimycin A for 20 min at room
temperature. We used the FL1, FL2 and FL3 channels of
a FACScalibur flow cytometer (15 mW argon ion laser
tuned at 488 nm; CellQuest software, Becton Dickinson
Biosciences). Thresholds were adjusted by using non-
stained and stained cells for MitoSox-Red fluorescence.
Flow cytometric evaluation of Ca2+ by Fluo-3 AM assay
Intracellular calcium was measured by flow cytometry
using the cell permeant, Ca2+-sensitive fluorescent dye
Fluo-3 AM (Life technologies, Carlsbad, CA) [29]. After
treatment with SapC-DOPS for different time points, cells
were washed in serum-free Advanced-MEM media, and
incubated with Fluo-3 AM for 30 min at 37°C. Later, cells
were washed with HEPES (4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid) buffer, trypsinized and centrifuged
at 3,500 rpm for 5 min. The pellet was resuspended in
HEPES buffer and analyzed using FACS Calibur (Becton
Dickinson) with excitation at 488 nm and emission at
525 nm. Approximately 10,000 events were counted.
Western blotting
After treatment with SapC-DOPS, cells were trypsinized
and lysed with RIPA buffer (Sigma) containing protease
inhibitor (Thermo Pierce) for 30 min on ice. The lysates
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supernatant. Protein concentration was determined by
the BCA method (Thermo Fischer Scientific, Rockford,
IL). Equal amounts of proteins (30–50 μg) were
separated by 4-20% gradient sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred to PVDF membrane (Amersham). After blocking,
the membrane was incubated overnight at 4°C with pri-
mary antibodies. Following this, blots were probed with
the appropriate Li-COR secondary antibodies conjugated
with IRDye 800 CW or IRDye 680 LT. Proteins were visu-
alized using an Odyssey IR scanner and quantified using
Odyssey software (LI-COR Biosciences, Lincoln, NE).
Mitochondrial and cytosolic fractionation
The mitochondrial and cytoplasmic fractions were sepa-
rated using the Mitochondrial/Cytosol fractionation kit
(BioVision, CA, USA) as per the manufacturer’s instruc-
tions. Briefly, whole-cell pellets dissolved in cytosolic
fraction extraction buffer were subjected to 55 strokes in
a 2 ml Dounce homogenizer on ice. The homogenate
was centrifuged at 3,500 rpm for 10 min at 4°C to pellet
nuclei and unbroken cells. The supernatant was subse-
quently centrifuged at 13,000 rpm for 30 min at 4°C to
obtain cytosolic supernatant and the mitochondrial pel-
let. Mitochondrial pellets were resuspended in mito-
chondrial extraction buffer by gentle vortex for 30 sec.
Bax oligomerization and bax inhibition
Bax oligomerization with cross linking was detected as
described previously [27]. Briefly, cells after treatment
with SapC-DOPS cells were washed in conjugating buffer
followed by cross linking with 2 mM disuccinyl suberate
in non-reducing buffer and incubated for 30 min at room
temperature. Reaction was quenched by addition of Tris–
HCl (pH 7.5) and incubation at room temperature for
15 min. The samples were then solubilized in lysis buffer
containing Nonidet P-40 without a reducing agent and
centrifuged at 12,000 x g for 10 min. Bax oligomers were
detected using the A67 clone that exclusively detects the
polymerized form. Bax inhibition was performed as de-
scribed earlier [30]. Briefly, cells were pre-incubated with
Bax inhibiting peptide (V5) or negative control peptide
(EMD Millipore,Chicago, IL) for one hour, prior to SapC-
DOPS treatment.
Lentiviral infection and stable knockdown of Smac/Diablo
Permanent knockdown of Smac was achieved by expres-
sion of pre-validated shRNA targeting the sequence
CCGACAATATACAAGTTTACT in Smac (shSmac)
available as clone ID TRCN04513 in the Sigma-TRC
consortium database. DNA oligonucleotides encoding
for shSmac were annealed and cloned into pLKO.1 puro.
Lentivirus particles carrying shSmac were produced bytransfecting 293T cells with pLKO.1-puro-shSmac to-
gether with viral packaging vectors (psPAX2, pMD2G)
by calcium phosphate transfection at the Cincinnati
Children’s Hospital Medical Center viral vector core fa-
cility. Three days post infection of SK-N-SH cells with
Smac shRNA containing virus, cells were selected in a
medium containing puromycin (Life Technologies,
Grand Island, NY). Efficiency of the knockdown was
checked by Western blot. Cells transfected with the
empty vector served as control.
Statistical analysis
Data are represented as the mean ± SE. Statistical ana-
lyses were done with the Student’s t test and P < 0.05
was considered significant.
Results
SapC-DOPS targets neuroblastoma and inhibits tumor
growth in vivo
Saposin C and dioleoylphosphatidylserine were assembled
(pH 5.0) at a molar ratio of 1:7 for in vivo studies or 1:3
for in vitro studies. Tumor targeting was evaluated by
real-time fluorescent imaging, following an intravenous
injection of fluorescently (CVM)-labeled SapC-DOPS
nanovesicles (mouse 1), CVM-labeled DOPS (mouse 2),
or SapC + CVM (mouse 3) in nude mice bearing human
neuroblastoma xenografts produced by flank injections of
CHLA-20 cells. At 24 h post injection, fluorescent signal
was only detected in tumor-bearing mouse that received
CVM-labeled SapC-DOPS (Figure 1A).
To assess the therapeutic efficacy of SapC-DOPS on
neuroblastoma, mice bearing CHLA-20 neuroblastoma
xenografts were subjected to intratumoral injections of
SapC-DOPS (SapC = 4 mg/kg, DOPS = 2 mg/kg) or
phosphate buffered saline (PBS). Mice treated with
SapC-DOPS showed a significant inhibition of tumor
growth (P = 0.0097) and decreased tumor weight
(P < 0.0001) when compared to mice treated with PBS
(Figure 1B). Histological evaluation by hematoxylin-
eosin (H&E) and terminal deoxynucleotidyltransferase
dUTP nick end labeling (TUNEL) staining showed
extensive induction of apoptosis within neuroblastoma
tissue (Figure 1C, D) in the mouse xenografts. Since
SapC-DOPS showed specific tumor targeting and in-
duced apoptosis in mouse xenografts, we proceeded to
determine the mechanism behind apoptosis induction
in established neuroblastoma cell lines.
SapC-DOPS triggers apoptosis of neuroblastoma cells
We hypothesized that the characteristically acidic tumor
microenvironment facilitates the binding of SapC-DOPS
to exposed PS on tumor cells, activates lysosomal gluco-
sylceramide breakdown, and elevates ceramide levels
leading to apoptotic cell death [6]. Although elevated
Figure 1 (See legend on next page.)
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Figure 1 Preparation and tumor-targeting potential of SapC-DOPS in mice xenografts. A) Treatment of athymic nude mice bearing
neuroblastoma (CHLA-20) xenografts with CVM-labeled SapC-DOPS (1), CVM-DOPS (2) or SapC-CVM (3). Animals were imaged 24 h after injection
with exposure time of 1 s. Saposin C, 4.2 mg/kg; dioleoylphosphatidylserine, 2 mg/kg; CellVue Maroon, 6 μmol. B) Evaluation of tumor burden
in SapC-DOPS treated mice xenografts. Mice xenografts (n = 15) were treated with five intratumoral injections of SapC-DOPS (SapC 4 mg/kg,
DOPS 2 mg/kg) or PBS every 3 days and followed for tumor growth. C) Histological examination of the neuroblastoma tumor tissue in mice after
intratumoral injection of DOPS and SapC-DOPS. Original magnification: 1000x. D) Evaluation of apoptosis by TUNEL staining (arrows) in DOPS- and
SapC-DOPS treated tumors. Original magnification: 40x.
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molecules capable of regulating mitochondrial function
were reported earlier [8] the role of SapC-DOPS in
mitochondrial function was not critically evaluated. Via-
bility assays in cultured cells measured after 72 h,
showed that SapC-DOPS induced significant cell death
in a dose-dependent manner at a concentration of
15 μM or above in SK-N-SH and IMR-32 human neuro-
blastoma cells, but not in normal, human Schwann cells
[P < 0.001; Figure 2A]. In contrast, the maximum loss of
viability in Schwann cells when exposed to the highestFigure 2 SapC-DOPS induces apoptosis in neuroblastoma cell lines. A
the MTT assay. **represents the lowest concentration from which P value i
treatment with 350 μM DOPS or 50 μM SapC-DOPS. Arrows indicate morph
Original magnification: 20x). C) Changes in cell cycle following treatment o
percentage of cells in Sub-G1 region. *P < 0.05, **P < 0.001 when compared
bars, SE.concentration of 200 μM SapC-DOPS was only around
10-15%. IMR-32 cells proved to be more resistant to
SapC-DOPS than SK-N-SH cells, in as much as 200 μM
dose did not induce further cell death, after a 3 day culture
period. The microscopic changes observed were character-
istic of apoptosis and included irregular shapes, nuclear
chromatin condensation and cell shrinkage [Figure 2B, see
arrows]. Treatment with up to 350 μM DOPS alone did
not elicit cell death [Additional file 1: Figure S1A]. Like-
wise, SK-N-SH and IMR-32 cells treated with SapC did
not show any significant decrease in viability (data not) Viability of SK-N-SH, IMR-32 and human Schwann cells measured by
s significant i.e., < 0.001. B) Microscopic images of SK-N-SH cells after
ological changes such as cell shrinkage and chromatin condensation.
f SK-N-SH cells with 50 μM SapC-DOPS for 24 h. The value represents
to control. Points, mean of three to five independent experiments;
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stantial DNA fragmentation as indicated by the time-
dependent increase in sub-G0/G1 events [Figure 2C]. A
G6PD release assay, used to estimate necrotic cell death,
yielded negative results (P = 0.46; n = 5; Additional file 1:
Figure S1B) and further confirmed that apoptosis is the
predominant mechanism underlying SapC-DOPS-induced
cell death.
SapC-DOPS disrupts mitochondrial membrane potential
in neuroblastoma cells
Disruption of ΔΨM, which indicates mitochondrial dys-
function and loss of membrane integrity, is considered
an early step in apoptosis [31,32]. In healthy cells, the
potentiometric mitochondrial dye JC-1 preferentially ac-
cumulates within the mitochondria and spontaneously
aggregates into a polymer emitting red fluorescence. In
apoptotic, unhealthy cells with low potential, JC-1 re-
mains in monomeric form emitting green fluorescence.
Treatment of neuroblastoma cells with SapC-DOPS re-
sulted in pronounced loss of ΔΨM in both dose- and
time-dependent manners [Figure 3A]. The decrease in
red/green fluorescence ratio of JC-1 was significant (P <
0.001) after 4 h at a dose of 50 μM SapC-DOPS, with a
more pronounced effect at later times. At 24 h, 5 μM
was sufficient to significantly induce loss in ΔΨM (P <
0.01). Pretreatment with 50 μM BA, a ΔΨM stabilizer
[33], prevented loss of ΔΨM [Figure 3C], and signifi-
cantly attenuated SapC-DOPS induced cell death in SK-
N-SH cells [P < 0.001; Figure 3D]. These observations
suggest that a loss of ΔΨM underlies the induction of
neuroblastoma apoptosis by SapC-DOPS.
SapC-DOPS induces translocation of apoptogenic proteins
and oligomerization
During mitochondria-mediated apoptosis the outer
mitochondrial membrane becomes permeable, a process
that is necessary for apoptogenic protein release and
caspase activation [34]. Smac, Cyto c, and AIF are pro-
teins released to cytosol from mitochondria in response
to death stimuli [35]; Smac and Cyto c cause apoptosis
by caspase-dependent pathways whereas AIF works by
caspase-independent pathways [36]. As shown in
Figure 4A, treatment of SK-N-SH and IMR-32 cells with
SapC-DOPS caused an increase in the expression of AIF,
Smac and Cyto c. These changes were paralleled by a
marked increase in the active caspase-3 fragment, an
early execution phase signal in human neuroblastoma
[37], as well as in cleaved poly-ADP-ribose polymerase
(cPARP), a substrate of caspase-3. Partial decreases in
the expression levels of anti-apoptotic protein Bcl-2
were also observed, particularly in IMR-32 cells. Survi-
vin, a member of the XIAP family of anti-apoptotic pro-
teins, showed a transient increase at 6 h but returnednear baseline levels at 24 h post-treatment in both cell
lines. To determine whether SapC-DOPS causes a redistri-
bution of Smac and Cyto c to the cytosol, mitochondrial
as well as cytosolic levels of both proteins were estimated
simultaneously by Western blotting. These results showed
that Smac release preceded that of Cyto c (Figure 4B).
Control experiments performed in SK-N-SH cells showed
that DOPS alone did not alter the expression levels of
apoptotic proteins [Additional file 2: Figure S2A]. Like-
wise, no change in apoptotic protein expression was no-
ticed upon treatment of SK-N-SH and IMR-32 cells
with SapC alone (data not shown). These results dem-
onstrate that SapC-DOPS treatment increases AIF,
Smac and Cyto c protein levels, triggers a cellular redis-
tribution of Smac and Cyto c, and induces cPARP for-
mation and activation of caspase-3.
Bax activation is necessary for SapC-DOPS-induced
apoptosis
Bax, a crucial proapoptotic factor of the Bcl-2 family lo-
calizes to the cytosol but translocates to the mitochon-
dria in response to various apoptotic stimuli [38].
Relocated Bax molecules facilitate mitochondrial release
of Smac and/or Cyto c to the cytosol by forming
channels on the outer mitochondrial membrane via
homo- or hetero-dimerization with members of the per-
meability transition pore (PTP) such as the voltage-
dependent anionic channel (VDAC), the adenine nucleo-
tide translocator, and cyclophylin D, among others[39].
In untreated SK-N-SH and IMR-32 cells, Bax proteins
were predominantly found in the cytosolic fraction of
[Figure 4C]. SapC-DOPS treatment induced Bax trans-
location from the cytosolic to the mitochondrial com-
partment [Figure 4C]. Bax polymerization, detected with
a monoclonal antibody (6A7) that specifically recognizes
Bax oligomers [27], was confirmed in whole cell extracts
of SK-N-SH and IMR-32 cells [Figure 4D]. A sustained
increase in total Bax monomer expression was detected
6 h after treatment in both cell lines.
Relocation of Smac and Cyto c is independent of ROS
formation, Cyclophilin D channel activity and increased
Ca2+ levels
Loss of ΔΨM results in several deleterious intracellular
outcomes such as generation of ROS that promotes oxida-
tive stress and the subsequent release of mitochondrial
proteins Smac, Cyto c and AIF to the cytosol. Since gener-
ation of ROS has been shown to accelerate cell death in
neuroblastoma cells [40], we examined the effects of
SapC-DOPS on intracellular ROS formation. SapC-DOPS
treatment induced significant mitochondrial superoxide
formation, as shown by an increase in MitoSox-red fluor-
escence intensity, 24 h post-treatment, in both SK-N-SH
and IMR-32 cells [Additional file 1: Figure S1C and S1D].
Figure 3 SapC-DOPS induces loss of mitochondrial potential (ΔΨM). A) Dose- and time-dependent changes in ΔΨM evaluated by JC-1 ratio of
red and green fluorescence following SapC-DOPS treatment in SK-N-SH and IMR-32 cells. B) ΔΨM measured by JC-1 ratio in bongkrekic acid-pretreated
SK-N-SH cells following SapC-DOPS treatment for 24 h. C) Viability measured by MTT assay in SK-N-SH cells following pre-treatment with bongkrekic acid
(BA) and subsequent treatment with 50 μM SapC-DOPS for 72 h. *P < 0.05, **P < 0.001 when compared to control. Points, mean of three to five
independent experiments; bars, SE.
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ate whether apoptotic induction by SapC-DOPS is driven
by ROS or the intrinsic pathway. First, we blocked ROS
formation by pre-treating SK-N-SH cells with 2 mM NAC
and evaluated Smac and Cyto c relocation. Pretreatment
with NAC neither rescued cell viability (Figure 5A) nor
prevented Smac and Cyto c relocation from mitochondria
to cytosol (Figure 5B). These results suggest that induction
of ROS does not mediate the apoptotic effects of SapC-
DOPS and may be a secondary consequence of SapC-
DOPS action.
The permeability transition pore (PTP), an incom-
pletely characterized channel complex that may include
Bax, is a major determinant of the mitochondrial release
of Smac, Cyto c and AIF during apoptosis [41]. Todetermine the possible role of the PTP in SapC-DOPS
mediated mobilization of Smac and Cyto c, SK-N-SH
cells were pre-incubated with 1 μM cyclosporine A,
which blocks PTP opening by binding to cyclophilin D
[42] As shown in Figure 5C, PTP inhibition did not alter
the time-dependent relocation of Cyto c and Smac from
mitochondria to the cytosol. Elevation of intracellular
Ca2+ is an important trigger for PTP opening and the
subsequent release of apoptogenic proteins. Flow cyto-
metric analysis with the Ca2+-sensitive dye Fluo-3 AM
showed no changes in intracellular Ca2+ levels following
SapC-DOPS treatment [Figure 5D]. These results show
that SapC-DOPS induces mitochondrial Smac and Cyto
c release without mediation by Cyclophilin D/PTP or
Ca2+.
Figure 4 SapC-DOPS treatment causes redistribution of apoptogenic proteins and Bax oligomerization in mitochondria of neuroblastoma
cells. A) Immunoblots from whole cell extracts showing apoptotic protein expression changes following treatment with 50 μM SapC-DOPS. Fractions
indicate fold-change estimated by densitometric analysis of proteins normalized to β-Actin corresponding to the lane. Fold change indicated for
caspase-3 corresponds to the cleaved 19 kDa fragment. Right lanes: (−) refers to negative control (Schwann cells treated with SapC-DOPS) and (+)
refers to positive control (SK-N-SH cells treated with 10 μM staurosporine) for 24 h. B) Relocation of Smac and Cyto c in SK-N-SH cells. Cox4 and
Tubulin served as loading control for the mitochondrial and cytoplasmic fractions, respectively. C) Bax redistribution in neuroblastoma cells
following SapC-DOPS treatment. D) Bax oligomerization in neuroblastoma cells. **P < 0.001. Points, mean of three to five experiments; bars, SE.
Western blots are representative of three independent experiments.
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Figure 5 Apoptotic redistribution of Smac and Cyto c is independent of ROS formation, Cyclophilin D activity and Ca2+. A) Effect of
N-acetyl cysteine (NAC)-mediated ROS inhibition on viability of SK-N-SH cells following SapC-DOPS treatment. B) Effect of pretreatment with
2 mM N-acetyl cysteine (NAC) following SapC-DOPS (50 μM) treatment on Smac and Cyto c relocation in SK-N-SH cells. C) Effect of 1 μM
cyclosporine A (CsA)-pretreatment on Smac and Cyto c relocation following SapC-DOPS (50 μM) treatment in SK-N-SH cells. D) Flow cytometric
measurement of Ca2+ using Fluo-3 AM in SK-N-SH cells treated with 50 μM SapC-DOPS. Values represent geometric mean of fluorescence. Points,
mean of three to five experiments; bars, SE. Western blots are representative of three independent experiments.
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apoptosis
Studies have shown that Smac/Diablo protein release can
occur independently of Cyto c release from the mitochon-
dria during apoptosis [22,23]. As noted above, Smac releaseoccurred by 6 h, the earliest time point in our study that
coincided with caspase-3 and PARP cleavage. Therefore, to
assess the relevance of Smac in SapC-DOPS-induced apop-
tosis, we performed shRNA-mediated Smac knockdown in
SK-N-SH cells. Cells were transfected with 50 nM lentiviral
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time. Whole cell immunoblots confirmed significantly de-
creased Smac protein levels, as measured 48 h after trans-
fection, with selective protein knockdown of >96%
[Additional file 2: Figure S2B]. Apoptosis-related off-target
effects were ruled out by comparing levels of Cyto c in con-
trol and shSmac-treated cells. Knocking down Smac ex-
pression significantly decreased SapC-DOPS-induced
apoptosis as denoted by reduced cell death (P < 0.001;
Figure 6A), and prevented the ΔΨM loss, reflected by in-
creased JC-1 red/green fluorescence ratio (Figure 6B).
While Smac knockdown did not affect mitochondrial re-
lease of AIF and Cyto c, the translocation of Bax to mito-
chondria was abrogated [Figure 6C] and the expression of
cleaved caspase-3 fragments was significantly attenuated in
SapC-DOPS-treated SK-N-SH cells [P < 0.01; Figure 6D].
Taken together, these findings suggest that Smac plays a
critical functional role in SapC-DOPS-induced apoptosis.
Because SapC-DOPS induces Bax translocation and
oligomerization, we questioned whether Bax is necessary
for its pro-apoptotic action. SK-N-SH cells were treated
with the Bax-inhibitory peptide V5 (50 μM) or a control
peptide (50 μM) for 30 min followed by treatment with
50 μM SapC-DOPS. Suggesting an important role for
Bax in the mitochondrial depolarization caused by SapC-
DOPS, V5 pretreatment led to a significant reduction in
cell death [P < 0.001; Figure 7A] and attenuation of ΔΨM
loss [Figure 7B]. Consistent with decreased apoptosis, Bax
inhibition also attenuated Smac and Cyto c mitochondrial
release and reduced caspase-3 activation [Figure 7C, 7D].
Pretreatment with the control peptide neither inhibited
Bax nor decreased SapC-DOPS-induced apoptosis. These
results indicate that Bax is a critical player during SapC-
DOPS induced apoptosis.
In summary, these findings strongly suggest that
SapC-DOPS preferentially induces apoptosis in neuro-
blastoma by a mitochondrial-mediated pathway.
Discussion
This study shows that SapC-DOPS, an antitumor agent
formed by the naturally-occurring protein Saposin C
and DOPS, targets neuroblastoma cells and inhibits
neuroblastoma growth in vitro and in vivo. Previous
work from our lab has shown that the preferential tar-
geting of SapC-DOPS nanovesicles to cancer cells, while
sparing normal ones, is due to higher levels of exposed
phosphatidylserine on their outer membranes [1,6-10].
Upon cell binding, SapC-DOPS is internalized and SapC
activates lysosomal hydrolases that degrade glucosylcera-
mide and sphingomyelin, resulting in the accumulation
of ceramide [8], a well-known apoptosis inducer [18]. In
the present study we perform a detailed analysis of
SapC-DOPS actions in two neuroblastoma cell lines, and
reveal that tumor toxicity results from mitochondrial-mediated apoptosis triggered by disrupted ΔΨM, mito-
chondrial release of Cyto c and Smac, Bax relocation
and oligomerization, and activation of Caspase 3. With
the efficacy of SapC-DOPS having been confirmed in
numerous solid tumor models [1,6,8-10], the elucidation
of SapC-DOPS mode of action is of critical importance
to design clinical trials, predict clinical outcomes as well
as anticipate and manage potential adverse effects.
Our in vitro results show that SapC-DOPS exerts dose-
dependent cytotoxicity in IMR-32 and SK-N-SH neuro-
blastoma cells, but have little effect on the viability of nor-
mal Schwann cells. Treated neuroblastoma cell cultures
showed microscopy features typical of apoptosis, including
cell shrinkage and chromatin condensation, while flow cy-
tometric analysis of DNA content showed progressive
DNA fragmentation. On the other hand, necrotic cell
death was ruled out, as evidenced by a G6PD assay. Next,
we addressed the molecular bases of SapC-DOPS induced
apoptosis, by first evaluating possible changes in ΔΨM.
Mitochondria maintain ΔΨM by controlling ion transport
via channels residing in the inner and outer mitochondrial
membranes. Loss of ΔΨM is an early requirement of apop-
tosis [43] and precedes chromatin condensation [44]. Upon
induction of apoptosis, a series of events induce mitochon-
drial outer membrane permeabilization (MOMP), altering
ΔΨM. Under certain conditions loss of ΔΨM acts as an
initiator, whereas in others it follows its onset [45]. MOMP
is mainly controlled by the Bcl-2 family of proteins that ei-
ther reside on the mitochondrial membrane, or reassemble
there after translocation from cytoplasm. Upon
oligomerization, they form new channels that release mito-
chondrial apoptogenic proteins like Cyto c, Smac and AIF.
We show here that SapC-DOPS nanovesicles induce,
within 6 h, a significant decrease in ΔΨM, which is paral-
leled by a decrease in mitochondrial Smac and increased
cPARP and caspase 3 cleavage, denoting apoptotic cell
death. Loss of ΔΨM is critical for SapC-DOPS tumor tox-
icity, as cell viability was significantly rescued following
pre-treatment of cells with the ΔΨM stabilizer agent BA.
Further experiments showed that SapC-DOPS induced a
delayed release (by 24 h) of other important pro-apoptotic
proteins, namely Cyto c and AIF, as well as translocation of
Bax from cytosol to mitochondria with oligomerization of
Bax monomers.
The nature and specificity of mitochondrial protein
channels and their individual preferences towards the
apoptogenic proteins Smac and Cyto c is under intense
debate [46]. However, accumulating evidence suggests
that several channels function independently or in
conjunction with the Bcl-2 family to determine the in-
ternal milieu of the organelle [41,47]. The phenomenon
termed “mitochondrial permeability transition” (MPT)
reflects the opening of the mitochondrial permeability
transition pore (PTP), triggering an influx of water into
Figure 6 Smac plays an important role in SapC-DOPS-induced apoptosis. A) SK-N-SH cell viability assessed by MTT assay after treatment
with 50 nM control scrambled shRNA (empty bars) or 50 nM Smac shRNA (filled bars) and subsequent SapC-DOPS treatment B) Evaluation of
ΔΨM by JC-1 assay in Smac-knockdown SK-N-SH cells following 50 μM SapC-DOPS treatment for 24 h. Pos CTL refers to treatment with 50 μM
2-[2-(3-Chlorophenyl)hydrazinylyidene]propanedinitrile (CCCP). C) Redistribution of apoptogenic proteins following 50 μM SapC-DOPS treatment
for 24 h in Smac-knockdown SK-N-SH cells. (D) Caspase-3 activation in SapC-DOPS (50 μM) treated Smac-knockdown SK-N-SH cells. Densitometry
graph shows relative changes in cleaved caspase-3 fragment expression normalized to β-Actin. *P < 0.05, **P < 0.001. Points, mean of three to five
experiments; bars, SE. Western blots are representative of three independent experiments.
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in MOMP, which promotes apoptotic caspase-dependent
and –independent cell death. VDAC, ANT, Cyclophilin
D and the Translocator protein (18 kD) are putative
constituents of the PTP [47,48], although knockout ex-
periments have shown VDAC and ANT to be dispens-
able for MPT-driven MOMP, suggesting that alternatechannels may regulate cell death [48]. Pre-treatment
with cyclosporine A, which inhibits the PTP by binding
to Cyclophilin D, failed to prevent SapC-DOPS-induced
mitochondrial efflux of Smac or Cyto c. Mitochondrial
Ca2+ overload is a critical activator of the PTP [49]. In
this study, however, flow cytometry with the Ca2+-sensi-
tive dye Fluo-3 AM showed that total intracellular Ca2+
Figure 7 Bax inhibition reduces SapC-DOPS-induced apoptosis. A) MTT assay in control peptide-treated (empty bar) and V5 peptide-treated
(Bax-inhibited; filled bars) SK-N-SH cells following SapC-DOPS treatment. B) ΔΨM measured by JC-1 assay in SK-N-SH cells following SapC-DOPS
treatment for 24 h. C) Apoptotic protein expression in control-peptide and Bax-V5-peptide pre-treated SK-N-SH cells following 50 μM SapC-DOPS
treatment for 24 h. D) Changes in Smac expression in cytosolic and mitochondrial extracts of Bax-inhibited SK-N-SH cells treated with 50 μM
SapC-DOPS. *P < 0.05, **P < 0.001. Points, mean of three to five experiments; bars, SE. Western blots are representative of three
independent experiments.
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treatment. Collectively these results indicate that neither
Cyclophilin D-mediated PTP opening nor intracellular
Ca2+ elevations are critical for SapC-DOPS-induced
apoptosis of neuroblastoma cells.
Bax oligomerization is proposed to form megachannels
in the outer mitochondrial membrane facilitating pro-
apoptotic protein release [36]. In support of an essential
role of Bax, we observed that mitochondrial Bax trans-
location is rapid following SapC-DOPS treatment, and is
necessary for Smac and Cyto c release from the mito-
chondria. However, significant oligomerization of Bax is
only noticed at 24 h, which coincides with the peak of
Smac and Cyto c release from the mitochondria. Al-
though many studies suggest that in the absence of Bax
no cytosolic Smac release occurs [50], there are reports
which show that cytotoxins [51] as well as apoptosis in-
ducers such as AT-101 [27] directly target mitochondriaand trigger Smac release irrespective of Bax activation.
In the present study, Bax inhibition led to complete loss
of cytosolic Smac release and an attenuated apoptosis as
seen by diminished Cyto c release and caspase-3 activa-
tion. These results indicate that Bax is required for
SapC-DOPS induced apoptosis. However, the trigger for
Bax polymerization is currently unknown. ROS forma-
tion may trigger Bax conformational change and trans-
location [52]. Consistent with this, we observed an
increase in ROS formation by 6 h after SapC-DOPS
treatment. However, generation of ROS is not required
for apoptosis induction since pretreatment with ROS
scavenger, N-acetyl cysteine (NAC) failed to prevent
SapC-DOPS-induced cytosolic Smac and Cyto c release.
Therefore, our results imply that SapC-DOPS-induced
ROS formation is not critical for apoptosis, but may en-
hance Bax oligomerization to form megachannels. The
relationship between Smac release and Bax activation is
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chondrial release pointed to a crucial role for Smac in
SapC-DOPS induced apoptosis. It has been reported that
initial Smac release requires active caspases [53], and we
observed caspase activation corresponding to this time
point. In general, during apoptosis the temporal release of
Cyto c from mitochondria precedes Smac release [54].
However, some anticancer drugs selectively release Smac
rather than Cyto c [55]. In agreement with the latter, we
noticed selective cytosolic Smac release at the early stages
of SapC-DOPS-induced apoptosis, whereas Cyto c release
was not evident until 24 h. A marked increase in cell viabil-
ity, retention of ΔΨM and reduction in SapC-DOPS in-
duced apoptosis as seen by a decrease in cytosolic AIF and
Cyto c release in Smac knockout cells further confirmed
the essential role of Smac. These results are consistent with
other reports that show Smac as an essential pro-apoptotic
molecule that determines anticancer activity [56].
The two human neuroblastoma cell lines we used in the
present study have been shown to differ in their expres-
sion of MYCN protein, which plays an important role in
the synergistic activation of Smac in some neuroblastoma
cells [57]. However, we observed that SapC-DOPS induced
mitochondrial Smac and Cyto c release pattern was simi-
lar in the two neuroblastoma cell lines examined, despite
different MYCN status. Further studies may be needed to
clarify if SapC-DOPS-induced Bax oligomerization culmi-
nates in Smac release independently, or in combination
with other Bcl-2 family members.
In summary, our present findings indicate that SapC-
DOPS shows selective in vivo tumor targeting and exert
significant tumor inhibition in mice bearing human neuro-
blastoma xenografts. Apoptosis was observed in vivo and
in vitro and occurred through a mitochondrial pathway as
demonstrated by a loss of mitochondrial ΔΨM and in-
creased mitochondrial superoxide formation, with mito-
chondrial release of apoptogenic proteins such as AIF,
Smac and Cyto c, and mitochondrial translocation and
polymerization of cytosolic Bax. Gene knockdown and in-
hibition studies established Smac and Bax as major regula-
tors of SapC-DOPS-induced apoptosis of neuroblastoma
cells. These results, and the benign safety profile evidenced
by several studies, suggest that SapC-DOPS may provide an
effective therapeutic approach against neuroblastoma.Additional files
Additional file 1: Figure S1. Evaluation of necrosis and mitochondrial
superoxide formation. A) MTT assay of SK-N-SH cells treated with DOPS. B)
Necrosis measured by G6PD release in SK-N-SH cells following treatment with
SapC, DOPS and SapC-DOPS for 24 h. C) Mean MitoSox-Red fluorescence
following 50 μM SapC-DOPS treatment of neuroblastoma cells for 24 h. Pos
CTL stands for pre-treatment with 20 μM Antimycin A. D) Quantification of
fold changes in MitoSox intensity after treatment with 50 μM SapC, 350 μM
DOPS or SapC-DOPS (25, 50 μM) for 24 h.Additional file 2: Figure S2. Protein expression analysis in SK-N-SH
cells. A) Expression of apoptotic proteins following treatment with
350 μM DOPS. Fractions indicate fold-change estimated by densitometric
analysis of proteins normalized to β-Actin corresponding to the lane.
B) ShRNA-mediated knockdown of Smac in SK-N-SH cells. Percentages
represent reduction in Smac normalized to β-Actin.
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